TITLE

Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment

AUTHOR(S)
Lin, Mao; Liang, Shuzhen; Wang, Xiaohua; Liang, Yinqing; Zhang, Mingjie; Chen, Jibing; Niu, Lizhi; Xu, Kecheng
PUB. DATE
December 2017
SOURCE
Journal of Cancer Research & Clinical Oncology;Dec2017, Vol. 143 Issue 12, p2607
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: This study was attempted to investigate the safety and clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell therapy for treating stage III/IV pancreatic cancer, evaluate median progression-free survival (PFS), and overall survival (OS). Methods: Between March 2016 and February 2017, we enrolled 67 patients who met the enrollment criteria. According to the latest NCCN Guidelines, the patients were divided into stage III (35 patients, 16 patients received only irreversible electroporation (IRE) and 19 patients received IRE-NK: 8 patients underwent one course NK and 11 patients underwent ≥3 courses) and stage IV (32 patients, 14 patients received only IRE and 18 patients received IRE-NK: 8 patients underwent one course NK and 10 patients underwent ≥3 courses). The safety and short-term effects were evaluated first, then the median PFS, median OS, response rate (RR) and disease control rate (DCR) were assessed. Results: Adverse events of all patients were limited to grades A and B, included local (mainly cough 12.7%, nausea and emesis 6.8%, pain of puncture point 25.3% and duodenum and gastric retention 5.9%) and systemic (mainly fatigue 21.5, fever 33.5%, and blood pressure intraoperative transient reduction 27.4% and white cell count reduction 22.6%) reactions, fever was most frequent. The serum amylase level at 24 h and 7 d after IRE was not significantly changed compared to those before IRE ( P > 0.05). CA19-9 value was lower in IRE-NK group than in IRE at 1 month after treatment ( P < 0.05). After a median follow-up of 7.9 months (3.8-12.1 months): in stage III group, median PFS was higher in IRE-NK group (9.1 months) than in IRE group (7.9 months, P = 0.0432), median OS was higher in IRE-NK (13.6 months) than in IRE (12.2 months; P = 0.0327), and median PFS was higher in who received multiple NK than single NK (9.9 vs. 8.2 months; P = 0.0387, respectively), median OS who received multiple NK was higher than single NK (13.7 vs. 12.1 months; P = 0.0451, respectively), the RR in IRE-NK (63.2%) was higher than in IRE (50.0%; P < 0.05); in stage IV group, median OS was higher in IRE-NK (10.2 months) than in IRE (9.1 months; P = 0.0367), the DCR in IRE-NK (66.7%) was higher than in IRE (42.9%; P < 0.05). Conclusion: Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy significantly increased median PFS and median OS in stage III pancreatic cancer and extended the median OS of stage IV pancreatic cancer. Multiple allogeneic natural killer cells infusion was associated with better prognosis to stage III pancreatic cancer.
ACCESSION #
126306470

 

Related Articles

  • The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Linn, Y-C; Niam, M; Chu, S; Choong, A; Yong, H-X; Heng, K-K; Hwang, W; Loh, Y; Goh, Y-T; Suck, G; Chan, M; Koh, M // Bone Marrow Transplantation;Jul2012, Vol. 47 Issue 7, p957 

    We performed a Phase I/II clinical trial to study the feasibility, toxicity and efficacy of allogeneic cytokine-induced killer (CIK) cell expansion, and treatment for patients with haematological malignancies who relapsed after allogeneic haemopoietic SCT (allo-HSCT). Allogeneic CIK cells were...

  • Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice. Yang Li; Yu-hua Qu; Yan-feng Wu; Xiao-ping Wang; Jing Wei; Wen-ge Huang; Dun-hua Zhou; Jianpei Fang; Ke Huang; Shao-liang Huang // Annals of Hematology;Aug2011, Vol. 90 Issue 8, p873 

    doptive cellular immunotherapy is an important treatment to eliminate residual tumor cells after hematopoietic stem-cell transplantation. Bone marrow mesenchymal stem cells (MSC) have previously been shown to exert immunoregulation functions, including inhibition of proliferation and killing...

  • Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Stern, M; Passweg, J R; Meyer-Monard, S; Esser, R; Tonn, T; Soerensen, J; Paulussen, M; Gratwohl, A; Klingebiel, T; Bader, P; Tichelli, A; Schwabe, D; Koehl, U // Bone Marrow Transplantation;Mar2013, Vol. 48 Issue 3, p433 

    Adoptive immunotherapy with allogeneic purified natural killer (NK) cell products might exert graft-versus-tumor alloreactivity with little risk of GVHD. In a prospective phase II study in two centers, we administered purified NK cell products to high-risk patients treated with haploidentical...

  • Blocking KCa3.1 Channels Increases Tumor Cell Killing by a Subpopulation of Human Natural Killer Lymphocytes. Koshy, Shyny; Wu, Danli; Hu, Xueyou; Tajhya, Rajeev B.; Huq, Redwan; Khan, Fatima S.; Pennington, Michael W.; Wulff, Heike; Yotnda, Patricia; Beeton, Christine // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Natural killer (NK) cells are large granular lymphocytes that participate in both innate and adaptive immune responses against tumors and pathogens. They are also involved in other conditions, including organ rejection, graft-versus-host disease, recurrent spontaneous abortions, and autoimmune...

  • Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Eiermann, T H; Lambrecht, P; Zander, A R // Bone Marrow Transplantation;4/15/99, Vol. 23 Issue 8, p779 

    The present study was undertaken to acquire a rationale for clinical dose adjustment of anti-thymocyte globulin (ATG) to improve cost effectiveness and safety of graft-versus-host disease prophylaxis. The concentration of rabbit ATG in the serum of 12 patients was measured by ELISA and by the...

  • Characterization and ex vivo expansion of human placenta-derived natural killer cells for cancer immunotherapy. Lin Kang; Voskinarian-Berse, Vanessa; Law, Eric; Reddin, Tiffany; Bhatia, Mohit; Hariri, Alexandra; Yuhong Ning; Dong, David; Maguire, Timothy; Yarmush, Martin; Hofgartner, Wolfgang; Abbot, Stewart; Xiaokui Zhang; Hariri, Robert // Frontiers in Immunology;May2013, Vol. 4, p1 

    Recent clinical studies suggest that adoptive transfer of donor-derived natural killer (NK) cells may improve clinical outcome in hematological malignancies and some solid tumors by direct anti-tumor effects as well as by reduction of graft versus host disease (GVHD). NK cells have also been...

  • Methylprednisolone induces preferential and rapid differentiation of CD34 cord blood precursors toward NK cells. Chiara Vitale; Francesca Cottalasso; Elisa Montaldo; Lorenzo Moretta; Maria Cristina Mingari // International Immunology;Apr2008, Vol. 20 Issue 4, p565 

    Previous studies showed that methylprednisolone (MePDN) down-regulates the surface expression of activating NK receptors and sharply inhibits the NK cytotoxicity both in vitro and in vivo. Since MePDN is administered to patients undergoing hemopoietic stem cell transplant to treat acute graft...

  • Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice. Willems, Leen; Fevery, Sabien; Sprangers, Ben; Rutgeerts, Omer; Lenaerts, Caroline; Ibrahimi, Abdelilah; Gijsbers, Rik; Van Gool, Stefaan; Waer, Mark; Billiau, An // Cancer Immunology, Immunotherapy;Nov2013, Vol. 62 Issue 11, p1733 

    Allogeneic hematopoietic stem cell transplantation and donor leukocyte infusion (DLI) may hold potential as a novel form of immunotherapy for high-risk neuroblastoma. DLI, however, carries the risk of graft-versus-host disease (GvHD). Recipient leukocyte infusion (RLI) induces...

  • Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1. Amarnath, Shoba; Costanzo, Carliann M.; Mariotti, Jacopo; Ullman, Jessica L.; Telford, William G.; Kapoor, Veena; Riley, James L.; Levine, Bruce L.; June, Carl H.; Fong, Timothy; Warner, Noel L.; Fowler, Daniel H. // PLoS Biology;Feb2010, Vol. 8 Issue 2, p1 

    Immunotherapy using regulatory T cells (Treg) has been proposed, yet cellular and molecular mechanisms of human Tregs remain incompletely characterized. Here, we demonstrate that human Tregs promote the generation of myeloid dendritic cells (DC) with reduced capacity to stimulate effector T cell...

  • Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas. Zomas, A.; Stefanoudaki, K.; Fisfis, M.; Papadaki, T.; Mehta, J. // Bone Marrow Transplantation;6/1/98, Vol. 21 Issue 11, p1163 

    Adoptive immunotherapy with donor leukocytes has emerged as a promising strategy for the treatment of myeloma recurrence after allogeneic transplantation. 2.9 x 10[sup8]/kg donor mononuclear cells containing 1.4% CD34+ and 37% CD3+ cells were administered to a 48year-old patient with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics